Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer

Neoplasia (United States)

Volumn 16, Issue 8, 2014, Pages 665-677

  Zhang, Tao ^a   Chen, Yihua ^a   Li, Jingjie ^a   Yang, Feifei ^a   Wu, Haigang ^a   Dai, Fujun ^a   Hu, Meichun ^a   Lu, Xiaoling ^c   Peng, Yi ^c   Liu, Mingyao ^a,b   Zhao, Yongxiang ^c   Yi, Zhengfang ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84991543731     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.07.009     Document Type: Article

References (53)

1. Hanahan D., Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70.
2. Bolden JE, Peart MJ, Johnstone RW Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
3. Khan O, Thangue La NB HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2011, 90:85-94.
4. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202.
5. Jacobson S, Pillus L Modifying chromatin and concepts of cancer. Curr Opin Genet Dev 1999, 9:175-184.
6. Johnstone RW Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1:287-299.
7. Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, et al. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003, 102:2615-2622.
8. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12:1247-1252.
9. Gryder BE, Sodji QH, Oyelere AK Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012, 4:505-524.
10. Tan J, Cang S, Ma Y, Petrillo RL, Liu D Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3:5-17.
11. Jemal A, Center MM, DeSantis C, Ward EM Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
12. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009, 101:1044-1050.
13. de la Vega M, Diaz-Canton E, Alvarez RH Novel targeted agents for the treatment of advanced breast cancer. Future Med Chem 2012, 4:893-914.
14. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 2008, 14:7138-7142.
15. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011, 104:1828-1835.
16. Zhang T, Li J, Dong Y, Zhai D, Lai L, Dai F, Deng H, Chen Y, Liu M, Yi Z Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion. Breast Cancer Res Treat 2012, 135:445-458.
17. Fang Y, Chen Y, Yu L, Zheng C, Qi Y, Li Z, Yang Z, Zhang Y, Shi T, Luo J, et al. Inhibition of breast cancer metastases by a novel inhibitor of TGFbeta receptor 1. J Natl Cancer Inst 2013, 105:47-58.
18. Gediya LK, Chopra P, Purushottamachar P, Maheshwari N, Njar VC A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem 2005, 48:5047-5051.
19. Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Mol Cancer Ther 2009, 8:1589-1595.
20. Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, Wu Y, Song Y, Luo J, Pang X, et al. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway. Carcinogenesis 2010, 31:2097-2104.
21. Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009, 15:3472-3483.
22. Khare V, Lyakhovich A, Dammann K, Lang M, Borgmann M, Tichy B, Pospisilova S, Luciani G, Campregher C, Evstatiev R, et al. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol 2012, 85:234-244.
23. Song Y, Dai F, Zhai D, Dong Y, Zhang J, Lu B, Luo J, Liu M, Yi Z Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis 2012, 15:421-432.
24. Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D, Coukos G, Zhang L, Huang Q KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009, 11:1297-1304.
25. Pan X, Han H, Wang L, Yang L, Li R, Li Z, Liu J, Zhao Q, Qian M, Liu M, et al. Nitidine chloride inhibits breast cancer cells migration and invasion by suppressing c-Src/FAK associated signaling pathway. Cancer Lett 2011, 313:181-191.
26. DeLisser H, Liu Y, Desprez PY, Thor A, Briasouli P, Handumrongkul C, Wilfong J, Yount G, Nosrati M, Fong S, et al. Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression. Proc Natl Acad Sci U S A 2010, 107:18616-18621.
27. Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, Street SE, Cameron R, Tanner JE, Trapani JA, et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 2004, 173:2143-2150.
28. Somech R, Izraeli S, A JS Histone deacetylase inhibitors - a new tool to treat cancer. Cancer Treat Rev 2004, 30:461-472.
29. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
30. Yan L, Donze JR, Liu L Inactivated MGMT by O6-benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. Oncogene 2005, 24:2175-2183.
31. Yang F, von Knethen A, Brune B Modulation of nitric oxide-evoked apoptosis by the p53-downstream target p21(WAF1/CIP1). J Leukoc Biol 2000, 68:916-922.
32. Zhao H, Ho PC, Lo YH, Espejo A, Bedford MT, Hung MC, Wang SC Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. PLoS One 2012, 7:e29416.
33. Yang CJ, Wang CS, Hung JY, Huang HW, Chia YC, Wang PH, Weng CF, Huang MS Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumor growth in an animal model. Lung Cancer 2009, 66:162-168.
34. Han J, Kim S, Yang JH, Nam SJ, Lee JE TPA-induced p21 expression augments G2/M arrest through a p53-independent mechanism in human breast cancer cells. Oncol Rep 2012, 27:517-522.
35. Brauns SC, Dealtry G, Milne P, Naude R, Van de Venter M Caspase-3 activation and induction of PARP cleavage by cyclic dipeptide cyclo(Phe-Pro) in HT-29 cells. Anticancer Res 2012, 72:4130-4140.
36. Chen J, Gallo KA MLK3 regulates paxillin phosphorylation in chemokine-mediated breast cancer cell migration and invasion to drive metastasis. Cancer Res 2012, 25:4197-4202.
37. Chen LC, Tu SH, Huang CS, Chen CS, Ho CT, Lin HW, Lee CH, Chang HW, Chang CH, Wu CH, et al. Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway. Breast Cancer Res Treat 2012, 134:989-1004.
38. Deakin NO, Turner CE Distinct roles for paxillin and Hic-5 in regulating breast cancer cell morphology, invasion, and metastasis. Mol Biol Cell 2011, 22:327-341.
39. Chen Q, Hongu T, Sato T, Zhang Y, Ali W, Cavallo JA, van der Velden A, Tian H, Di Paolo G, Nieswandt B, et al. Key roles for the lipid signaling enzyme phospholipase d1 in the tumor microenvironment during tumor angiogenesis and metastasis. Sci Signal 2012, 5:ra79.
40. Yuan K, Frolova N, Xie Y, Wang D, Cook L, Kwon YJ, Steg AD, Serra R, Frost AR Primary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissues. J Histochem Cytochem 2010, 58:857-870.
41. Deryugina EI, Quigley JP Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006, 25:9-34.
42. An Z, Gluck CB, Choy ML, Kaufman LJ Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. Cancer Lett 2010, 292:215-227.
43. Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasberg R, Massague J Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005, 115:44-55.
44. Valastyan S, Weinberg RA Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
45. Ponzone R, Baum M Loco-regional therapy and breast cancer survival: Searching for a link. Breast 2012, 22:510-514.
46. Huston TL, Simmons RM Locally recurrent breast cancer after conservation therapy. Am J Surg 2005, 189:229-235.
47. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000, 60:2710-2715.
48. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
49. Bergh J, Jonsson PE, Glimelius B, Nygren P A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001, 40:253-281.
50. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008, 14:3306-3311.
51. Steeg PS Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
52. Kessenbrock K, Plaks V, Werb Z Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 141:52-67.
53. Chen L, Yang S, Jakoncic J, Zhang JJ, Huang XY Migrastatin analogues target fascin to block tumour metastasis. Nature 2010, 464:1062-1066.